142 related articles for article (PubMed ID: 18798092)
1. Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124.
Molavi O; Ma Z; Hamdy S; Lavasanifar A; Samuel J
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):214-21. PubMed ID: 18798092
[TBL] [Abstract][Full Text] [Related]
2. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
4. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.
Alshamsan A; Haddadi A; Hamdy S; Samuel J; El-Kadi AO; Uludağ H; Lavasanifar A
Mol Pharm; 2010 Oct; 7(5):1643-54. PubMed ID: 20804176
[TBL] [Abstract][Full Text] [Related]
5. Self-Associating Poly(ethylene oxide)-block-poly(α-carboxyl-ε-caprolactone) Drug Conjugates for the Delivery of STAT3 Inhibitor JSI-124: Potential Application in Cancer Immunotherapy.
Garg SM; Vakili MR; Molavi O; Lavasanifar A
Mol Pharm; 2017 Aug; 14(8):2570-2584. PubMed ID: 28221800
[TBL] [Abstract][Full Text] [Related]
6. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
7. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
9. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.
Hamdy S; Elamanchili P; Alshamsan A; Molavi O; Satou T; Samuel J
J Biomed Mater Res A; 2007 Jun; 81(3):652-62. PubMed ID: 17187395
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations.
Hamdy S; Haddadi A; Somayaji V; Ruan D; Samuel J
J Pharm Biomed Anal; 2007 Aug; 44(4):914-23. PubMed ID: 17590559
[TBL] [Abstract][Full Text] [Related]
13. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine.
Jahan ST; Sadat SM; Haddadi A
Int J Nanomedicine; 2018; 13():367-386. PubMed ID: 29391795
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
Hamdy S; Molavi O; Ma Z; Haddadi A; Alshamsan A; Gobti Z; Elhasi S; Samuel J; Lavasanifar A
Vaccine; 2008 Sep; 26(39):5046-57. PubMed ID: 18680779
[TBL] [Abstract][Full Text] [Related]
16. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
Hamdy S; Haddadi A; Hung RW; Lavasanifar A
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
[TBL] [Abstract][Full Text] [Related]
17. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
18. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy.
Heo MB; Kim SY; Yun WS; Lim YT
Int J Nanomedicine; 2015; 10():5981-92. PubMed ID: 26451105
[TBL] [Abstract][Full Text] [Related]
19. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro.
Keijzer C; Spiering R; Silva AL; van Eden W; Jiskoot W; Vervelde L; Broere F
J Control Release; 2013 May; 168(1):35-40. PubMed ID: 23500056
[TBL] [Abstract][Full Text] [Related]
20. M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity.
Ma T; Wang L; Yang T; Ma G; Wang S
Int J Pharm; 2014 Oct; 473(1-2):296-303. PubMed ID: 24984067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
